Obesity directly affects kidney health and influences chronic kidney disease (CKD) risk and progression through contributing ...

The Food and Drug Administration (FDA) announced that it has accepted the New Drug Application (NDA) for UGN-102 for intravesical solution for the treatment of low-grade intermediate-risk non-muscle ...

Nine statements developed, including performing 4 or more versus 3 or fewer needle passes in suspected malignant disease.

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.

Of the about one-third receiving stimulant medication, 71.5% had difficulty filling prescription due to unavailability.